BA3 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Revenue And Biorepository MomentumA revenue mix with more than half recurring provides greater visibility than reliance on one-time instrument sales. Growing biorepository and consumables activity can support customer retention, utilization and steadier cash generation as research organizations outsource and automate sample management.
Conservative Balance SheetVery low leverage and a substantial equity cushion reduce refinancing and solvency risk while preserving financial flexibility. This balance-sheet strength gives Azenta capacity to continue investing in products, services and strategic initiatives through periods of uneven demand and profitability.
Multiomics Growth And Improving Gross MarginGrowth in Multiomics, supported by higher NGS and gene-synthesis volumes, indicates ongoing demand for genomic workflows. The substantial segment margin improvement shows operating leverage potential if volume growth persists, strengthening the business's ability to convert expansion into earnings.
Bears Say
Persistent Unprofitable OperationsAzenta has not yet demonstrated durable earnings conversion despite modest revenue stabilization. A deeply negative net margin and negative operating earnings can constrain internally funded investment, weaken returns on capital and make future performance highly sensitive to cost control and revenue mix.
Automated-store Execution And Margin PressureWeak automated-store bookings and unresolved customized systems point to execution challenges in an important solution area. Remediation spending and lower fixed-cost absorption pressure margins, while continued validation delays could postpone customer acceptance, revenue realization and recovery in profitability.
Structural Sanger Sequencing DeclineThe decline in Sanger sequencing reflects a lasting technology transition rather than a temporary order fluctuation. This can reduce demand and profitability in part of Multiomics, requiring Azenta to shift resources toward NGS and other growth areas while absorbing mix and transition costs.
Azenta News
BA3 FAQ
What was Azenta’s price range in the past 12 months?
Currently, no data Available
What is Azenta’s market cap?
Azenta’s market cap is CHF1.11B.
When is Azenta’s upcoming earnings report date?
Azenta’s upcoming earnings report date is Nov 17, 2026 which is in 69 days.
How were Azenta’s earnings last quarter?
Azenta released its earnings results on Aug 04, 2026. The company reported CHF0.129 earnings per share for the quarter, beating the consensus estimate of CHF0.092 by CHF0.037.
Is Azenta overvalued?
According to Wall Street analysts Azenta’s price is currently Undervalued.
Does Azenta pay dividends?
Azenta does not currently pay dividends.
What is Azenta’s EPS estimate?
Azenta’s EPS estimate is 0.13.
How many shares outstanding does Azenta have?
Currently, no data Available
What happened to Azenta’s price movement after its last earnings report?
Azenta reported an EPS of CHF0.129 in its last earnings report, beating expectations of CHF0.092. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Azenta?
Currently, no hedge funds are holding shares in CH:BA3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Azenta Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF28.36 (― Upside)
CHF28.36 (― Upside)
Blogger Sentiment
Bullish
CH:BA3 Sentiment 75%
Sector Average 60%
Sector Average 60%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Azenta
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
BA3 Company Deck
BA3 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflected a cautious but constructive tone: the company delivered a better-than-expected quarter with solid organic revenue growth (9%), sequential profitability improvement (adjusted EBITDA margin up ~610 bps sequentially) and progress on strategic initiatives (AI-enabled biorepository deployment, modular stores, UKBC integration, and B Medical divestiture). However, meaningful near-term headwinds remain — notably gross margin pressure (overall and in Sample Management Solutions), quality remediation costs ($5M–$6M expected), ongoing Sanger secular decline, negative quarterly free cash flow, and a difficult Q4 comp. Management emphasized disciplined execution and a measured outlook. Overall, positives around execution and a stronger outlook are balanced by persistent margin and demand uncertainties.View all CH:BA3 earnings summaries